Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00614250 | Evaluation of the Effect of AVE0657 on Obstructive Sleep Apnea | PHASE2 | COMPLETED | 38 | — | — | Jan 1, 2008 | Jan 1, 2009 | Jul 20, 2009 | 3 | France, Germany +1 |
| Arm | Type | Description |
|---|---|---|
| Dose Level 1 | EXPERIMENTAL | - |
| Dose Level 2 | EXPERIMENTAL | - |
| Dose Level 3 | EXPERIMENTAL | - |
| Dose Level 4 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | 12 subjects: 3 subjects per dose level |
| Name | Type | Description |
|---|---|---|
| AVE0657 | DRUG | capsules once a day at bedtime |
| placebo | DRUG | capsules once a day at bedtime |
Inclusion Criteria: * Subjects diagnosed with Obstructive Sleep Apnea Hypopnea Syndrome based on International Classification of Sleep Disorders Exclusion Criteria: * Subjects having been treated by Continuous Positive Airway Pressure, oral appliance during 4-weeks prior to randomization * Chroni...